{"nctId":"NCT02465632","briefTitle":"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.","startDateStruct":{"date":"2015-04"},"conditions":["Acne Vulgaris"],"count":1100,"armGroups":[{"label":"Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel","type":"EXPERIMENTAL","interventionNames":["Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel"]},{"label":"BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%"]},{"label":"Placebo topical gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel","otherNames":[]},{"name":"BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or non-pregnant, non-lactating female, ≥12 and ≤40 years of age with a clinical diagnosis of acne vulgaris.\n2. Have facial acne with: ≥20 facial inflammatory lesions (papules and pustules) and ≥25 non-inflammatory lesions (open and closed comedones), and ≤2 nodulocystic lesions (nodules and cysts) and have an IGA score of 2, 3 or 4.\n\nExclusion Criteria:\n\n1. Subject has more than 2 facial nodular lesions; any nodules present will be documented but not included in the inflammatory lesion count for analysis.\n2. Subject has active cystic acne.\n3. Subject has acne conglobata.\n4. Subjects with excessive facial hair such as beards, sideburns, moustaches, etc. that would interfere with the diagnosis or assessment of acne.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change in the Number of Inflamed Lesions (Papules/Pustules)","description":"The number of inflammatory lesions (papules and pustules) count between the treatment groups were estimated.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":"25.2"},{"groupId":"OG001","value":"71.1","spread":"26.7"},{"groupId":"OG002","value":"39.1","spread":"31.4"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in the Number of Non-inflamed Lesions (Open and Closed Comedones)","description":"The number of non-inflamed lesions (open and closed comedones) count between treatment groups were estimated.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":"24.7"},{"groupId":"OG001","value":"63.3","spread":"26.2"},{"groupId":"OG002","value":"30.9","spread":"28.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":432},"commonTop":[]}}}